Hemogenyx Pharmaceuticals Announces Recruitment of Second Patient in HG-CT-1 Clinical Trial for Acute Myeloid Leukemia
London, UK – Hemogenyx Pharmaceuticals plc (HEMO), a biopharmaceutical company focusing on the development of innovative gene therapies and immunotherapies, is proud to announce the successful recruitment of the second patient in its clinical trial of HG-CT-1, a proprietary Chimeric Antigen Receptor T-cell (CAR-T) therapy, for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) in adults. This milestone signifies a crucial advancement in Hemogenyx’s clinical development program, bringing hope to AML patients with limited therapeutic options.
Background on HG-CT-1 and Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a type of cancer that affects the production of white blood cells in the bone marrow. According to the American Cancer Society, approximately 21,000 new cases are diagnosed each year in the United States, and the five-year survival rate is around 24%. AML treatments include chemotherapy, bone marrow transplantation, and targeted therapies. However, these treatments have significant side effects and limitations, and many patients do not respond to current therapies.
About HG-CT-1
HG-CT-1 is a CAR-T cell therapy designed to target CD43, a protein expressed on the surface of AML cells. CAR-T cell therapies are a type of immunotherapy that uses genetically modified T cells to target and destroy cancer cells. HG-CT-1 has shown promising results in preclinical studies, demonstrating the potential to eliminate leukemia cells while minimizing damage to healthy cells.
Clinical Trial Progress
The recruitment of the second patient in the HG-CT-1 clinical trial is a significant achievement for Hemogenyx Pharmaceuticals. The trial, which is being conducted in multiple sites across Europe, is a Phase I/II open-label, multicenter study. The primary objective of the trial is to evaluate the safety, tolerability, and efficacy of HG-CT-1 in adult patients with R/R AML. The secondary objectives include assessing the pharmacokinetics, pharmacodynamics, and immunogenicity of HG-CT-1.
Impact on Patients and the World
For individual patients, the recruitment of the second patient in the HG-CT-1 clinical trial represents a potential lifeline. AML patients with relapsed or refractory disease have limited therapeutic options and often face poor prognoses. CAR-T cell therapies, such as HG-CT-1, offer a new hope for these patients, as they have shown significant promise in treating various types of cancer, including leukemia.
On a global scale, the progress of HG-CT-1 in clinical trials underscores the potential of CAR-T cell therapies to revolutionize cancer treatment. According to a report by Grand View Research, the global CAR-T cell therapy market is expected to grow at a compound annual growth rate (CAGR) of 49.5% from 2020 to 2027. The growing market size is attributed to the increasing prevalence of cancer, the rising adoption of CAR-T cell therapies, and the increasing investment in research and development.
Conclusion
The recruitment of the second patient in Hemogenyx Pharmaceuticals’ HG-CT-1 clinical trial marks a significant milestone in the development of a potentially life-saving treatment for relapsed or refractory acute myeloid leukemia. This achievement highlights the potential of CAR-T cell therapies to transform cancer treatment and offers hope to patients with limited therapeutic options. As the clinical trial progresses, we look forward to further advancements in this field and the potential to bring innovative therapies to patients in need.
- Hemogenyx Pharmaceuticals announces the recruitment of the second patient in the HG-CT-1 clinical trial for R/R AML.
- HG-CT-1 is a CAR-T cell therapy designed to target CD43, a protein expressed on the surface of AML cells.
- The clinical trial is a Phase I/II open-label, multicenter study evaluating the safety, tolerability, and efficacy of HG-CT-1 in adult patients with R/R AML.
- The progress of HG-CT-1 in clinical trials underscores the potential of CAR-T cell therapies to revolutionize cancer treatment and offers hope to patients with limited therapeutic options.
